Onyx Pharmaceuticals to Acquire Proteolix
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
Medicago, a Canadian company focused on protein-based vaccines, has signed a contract with the U.S. Army to investigate ways to create biofuels from plants.
Repros and Targacept have announced plans to offer shares in their respective companies at a reduced cost.
Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
Acadia and its partner Biovail made news last month with a failed late-stage trial of pimavanserin, their experimental drug candidate to treat psychosis related to Parkinson’s disease.
CVT’s system, currently under development, is the first self-conforming and self-anchoring technology for transcatheter mitral valve implantation (TVMI).
The race for an anti-obesity drug intensified Wednesday with the latest mid-stage trial data from Orexigen Therapeutics.
After a long delay, Centocor Ortho Biotech’s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration.
Follow OneMedPlace on Twitter to discover the latest happenings in the life sciences industry.
Copyright © 2025 | WordPress Theme by MH Themes